Proteomics in prostate cancer biomarker discovery

Despite advances in molecular medicine, genomics, proteomics and translational research, prostate cancer remains the second most common cause of cancer-related mortality for men in the Western world. Clearly, early detection, targeted treatment and post-treatment monitoring are vital tools to combat this disease. Tumor markers can be useful for diagnosis and early detection of cancer, assessment of prognosis, prediction of therapeutic effect and treatment monitoring. Such tumor markers include prostate-specific antigen (prostate), cancer antigen (CA)15.3 (breast), CA125 (ovarian), CA19.9 (gastrointestinal) and serum α-fetoprotein (testicular cancer). However, all of these biomarkers lack sensitivity and specificity and, therefore, there is a large drive towards proteomic biomarker discovery. Current research efforts are directed towards discovering biosignatures from biological samples using novel proteomic technologies that provide high-throughput, in-depth analysis and quantification of the proteome. Several of these studies have revealed promising biomarkers for use in diagnosis, assessment of prognosis, and targeting treatment of prostate cancer. This review focuses on prostate cancer proteomic biomarker discovery and its future potential.

[1]  D. Chan,et al.  Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. , 2008, Clinical chemistry.

[2]  S. Loening,et al.  Re: Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, Kiemeney LA, Witjes JA, Schalken JA. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-16. , 2004, European urology.

[3]  Ruedi Aebersold,et al.  Identification of androgen-coregulated protein networks from the microsomes of human prostate cancer cells , 2003, Genome Biology.

[4]  Bernadette Coles,et al.  The clinical management of patients with a small volume of prostatic cancer on biopsy: What are the risks of progression? , 2008, Cancer.

[5]  R. Vessella,et al.  LuCaP 35: A new model of prostate cancer progression to androgen independence , 2003, The Prostate.

[6]  P. Schellhammer,et al.  Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. , 2001, Cancer research.

[7]  J. Richie,et al.  Chromatofocusing fractionation and two‐dimensional difference gel electrophoresis for low abundance serum proteins , 2005, Proteomics.

[8]  Daniel B. Martin,et al.  Quantitative Proteomic Analysis of Proteins Released by Neoplastic Prostate Epithelium , 2004, Cancer Research.

[9]  H. Leung,et al.  Evaluation of an in vitro model of androgen ablation and identification of the androgen responsive proteome in LNCaP cells , 2007, Proteomics.

[10]  Eugenia G. Giannopoulou,et al.  Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry. , 2008, Journal of proteome research.

[11]  C. Stephan,et al.  Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. , 2008, Journal of proteome research.

[12]  E. Petricoin,et al.  Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.

[13]  John D Minna,et al.  Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  S. Pang,et al.  Proteomic comparison of prostate cancer cell lines LNCaP‐FGC and LNCaP‐r reveals heatshock protein 60 as a marker for prostate malignancy , 2006, The Prostate.

[15]  M. Rubin,et al.  Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. , 2009, Journal of proteome research.

[16]  Lori J Sokoll,et al.  Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. , 2009, Journal of proteome research.

[17]  A. Vlahou,et al.  Proteomic approaches to biomarker discovery in prostate and bladder cancers , 2001, Proteomics.

[18]  Arul M Chinnaiyan,et al.  Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. , 2003, Journal of the National Cancer Institute.

[19]  E. Kehinde.  The geography of prostate cancer and its treatment in Africa. , 1995, Cancer surveys.

[20]  M. Zvelebil,et al.  Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons , 2004, Oncogene.

[21]  U. Hellman,et al.  Correlation of protein expression, Gleason score and DNA ploidy in prostate cancer , 2006, Proteomics.

[22]  P. Schellhammer,et al.  Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. , 1995, Urologic oncology.

[23]  John T. Wei,et al.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.

[24]  Seongjoon Koo,et al.  PCA3: a molecular urine assay for predicting prostate biopsy outcome. , 2008, The Journal of urology.

[25]  P. Schellhammer,et al.  The pursuit of prostate cancer in patients with a rising prostate-specific antigen and multiple negative transrectal ultrasound-guided prostate biopsies. , 2002, Clinical prostate cancer.

[26]  Ian M Thompson,et al.  Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker , 2004, Cancer.

[27]  Guo Xiaojian,et al.  Unfavorable Prognostic Value of Human PEDF Decreased in High-Grade Prostatic Intraepithelial Neoplasia: A Differential Proteomics Approach , 2009, Cancer investigation.

[28]  P. Fisher,et al.  Molecular markers and determinants of prostate cancer metastasis , 2001, Journal of cellular physiology.

[29]  D. Ransohoff.  Bias as a threat to the validity of cancer molecular-marker research , 2005, Nature reviews. Cancer.

[30]  S. Gygi,et al.  Toward a high-throughput approach to quantitative proteomic analysis: Expression-dependent protein identification by mass spectrometry , 2001, Journal of the American Society for Mass Spectrometry.

[31]  J. Schalken,et al.  New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. , 2003, Urology.

[32]  O. Bratt.  Hereditary prostate cancer: clinical aspects. , 2002, The Journal of urology.

[33]  A. Vlahou,et al.  Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  J. McKiernan,et al.  Linkage disequilibrium between the androgen receptor gene CAG and GGC repeats in the African-American population , 2002, Current urology reports.

[35]  S. Naylor,et al.  Promise and Challenge: Markers of Prostate Cancer Detection, Diagnosis and Prognosis , 2004, Disease markers.

[36]  R. Dwek,et al.  Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA. , 2006, Glycobiology.

[37]  T. Stamey,et al.  Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .

[38]  D. Ghosh,et al.  Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases , 2004, Cancer Research.

[39]  Darren R Tyson,et al.  Proteomics for the identification of new prostate cancer biomarkers. , 2006, Urologic oncology.

[40]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[41]  Thomas P Conrads,et al.  The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. , 2002, Biochemical and biophysical research communications.

[42]  D. Chan,et al.  SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. , 2008, Clinical chemistry.

[43]  R. Millikan,et al.  Prostate cancer progression in the presence of undetectable or low serum prostate‐specific antigen level , 2007, Cancer.

[44]  L. Kiemeney,et al.  DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer , 2003 .

[45]  Y. Mechref,et al.  Alterations in the serum glycome due to metastatic prostate cancer. , 2007, Journal of proteome research.

[46]  Paul Tempst,et al.  Pathway-based biomarker search by high-throughput proteomics profiling of secretomes. , 2009, Journal of proteome research.

[47]  Daniel Hartmann,et al.  Identification of Potential Markers for the Detection of Pancreatic Cancer Through Comparative Serum Protein Expression Profiling , 2007, Pancreas.

[48]  Bao-xue Yang,et al.  Application of surface-enhanced laser desorption/ionization time-of-flight-based serum proteomic array technique for the early diagnosis of prostate cancer. , 2006, Asian journal of andrology.

[49]  P. Schellhammer,et al.  Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. , 2002, Clinical chemistry.

[50]  James C. Marsters,et al.  Selective Detection of Membrane Proteins Without Antibodies , 2002, Molecular & Cellular Proteomics.

[51]  M. Dunn,et al.  Application of proteomic strategies to the identification of urinary biomarkers for prostate cancer: A review , 2006, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[52]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[53]  Yue Fan,et al.  2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. , 2009, Journal of proteome research.

[54]  D. Ransohoff.  Rules of evidence for cancer molecular-marker discovery and validation , 2004, Nature Reviews Cancer.

[55]  Ishtiaq Rehman,et al.  iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression. , 2008, Journal of proteome research.

[56]  Hsueh-Kung Lin,et al.  Unique patterns of molecular profiling between human prostate cancer LNCaP and PC‐3 cells , 2009, The Prostate.

[57]  Katie L Meehan,et al.  Quantitative profiling of LNCaP prostate cancer cells using isotope‐coded affinity tags and mass spectrometry , 2004, Proteomics.

[58]  L. Kiemeney,et al.  DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. , 2002, Cancer research.

[59]  Mike Wilson,et al.  Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  J. Hanley,et al.  Competing Risk Analysis of Men Aged 55 to 74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer , 1998 .

[61]  J. Alper.  Turning Sweet on Cancer , 2003, Science.

[62]  Vetle I. Torvik,et al.  A statistical approach predicts human microRNA targets , 2004, Genome Biology.

[63]  M. Clements,et al.  Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. , 2009, Journal of proteomics.

[64]  Harry J de Koning,et al.  Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.

[65]  D. Bostwick,et al.  Human prostate cancer risk factors , 2004, Cancer.

[66]  A. Vlahou,et al.  Prostate-specific Membrane Antigen Levels in Sera from Healthy Men and Patients with Benign Prostate Hyperplasia or Prostate Cancer 1 , 1999 .

[67]  J. Cerhan,et al.  Prostate Cancer Trends 1973-1995, SEER Program National Cancer Institute. , 1999 .

[68]  A. Chokkalingam,et al.  Prostate cancer epidemiology. , 2006, Frontiers in bioscience : a journal and virtual library.

[69]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.

[70]  P. Dalbon,et al.  Differential diagnosis of prostate cancer and benign prostate hyperplasia using two‐dimensional electrophoresis , 2001, Electrophoresis.

[71]  James A Hanley,et al.  20-year outcomes following conservative management of clinically localized prostate cancer. , 2005, JAMA.

[72]  H. Berkel,et al.  Prostate-specific antigen (PSA) in women. , 1999, The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society.

[73]  D. Grignon,et al.  Diagnostic and prognostic markers for human prostate cancer , 1997, The Prostate.

[74]  Therese Miller,et al.  Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force , 2008, Annals of Internal Medicine.

[75]  J. Brooks,et al.  Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[76]  William E Grizzle,et al.  Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[77]  V. Margulis,et al.  New blood‐based biomarkers for the diagnosis, staging and prognosis of prostate cancer , 2008, BJU international.

[78]  C. Heyns,et al.  Prostate cancer: Prevalence and treatment in African men , 2005 .

[79]  G. Murphy,et al.  LNCaP model of human prostatic carcinoma. , 1983, Cancer research.